Tema ETF Trust. Holdings as of May 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Eli Lilly & CoLLY | 11.52% | $5.98M | 5,413 |
| AstraZeneca PLC | 4.00% | $2.80M | 11,178 |
| UnitedHealth Group IncUNH | 5.24% | $2.72M | 7,159 |
| Roche Holding AG | 4.50% | $2.33M | 44,538 |
| Novartis AG | 3.38% | $2.25M | 11,627 |
| Merck & Co IncMRK | 4.27% | $2.22M | 18,672 |
| Thermo Fisher Scientific IncTMO | 3.97% | $2.06M | 4,185 |
| Johnson & JohnsonJNJ | 3.59% | $1.86M | 8,274 |
| Gilead Sciences IncGILD | 3.43% | $1.78M | 13,261 |
| Revolution Medicines IncRVMD | 3.33% | $1.73M | 10,971 |
| Vertex Pharmaceuticals IncVRTX | 2.93% | $1.52M | 3,398 |
| Danaher CorpDHR | 2.66% | $1.38M | 7,557 |
| Abbott LaboratoriesABT | 2.61% | $1.35M | 15,809 |
| Bridgebio Pharma IncBBIO | 2.59% | $1.35M | 20,327 |
| Cytokinetics IncCYTK | 2.52% | $1.31M | 17,069 |
| AbbVie IncABBV | 2.40% | $1.24M | 5,714 |
| Bristol-Myers Squibb CoBMY | 2.09% | $1.08M | 18,939 |
| Teva Pharmaceutical Industries | 2.06% | $1.07M | 30,273 |
| Dexcom IncDXCM | 1.92% | $996.37K | 13,512 |
| Amgen IncAMGN | 1.91% | $992.18K | 2,946 |
| Medtronic PLC | 1.88% | $974.51K | 13,203 |
| Edwards Lifesciences CorpEW | 1.75% | $906.90K | 10,488 |
| McKesson CorpMCK | 1.71% | $887.96K | 1,196 |
| Regeneron Pharmaceuticals IncREGN | 1.67% | $865.61K | 1,408 |
| Madrigal Pharmaceuticals IncMDGL | 1.45% | $755.35K | 1,519 |
| Boston Scientific CorpBSX | 1.42% | $738.42K | 15,285 |
| Intuitive Surgical IncISRG | 1.30% | $675.18K | 1,590 |
| Alnylam Pharmaceuticals IncALNY | 1.14% | $590.07K | 1,954 |
| Arrowhead Pharmaceuticals IncARWR | 1.09% | $564.07K | 7,240 |
| Scholar Rock Holding CorpSRRK | 0.92% | $475.60K | 9,647 |
| Xenon Pharmaceuticals IncXENE | 0.88% | $459.35K | 8,393 |
| Ionis Pharmaceuticals IncIONS | 0.83% | $428.32K | 5,599 |
| Novo Nordisk A/S | 5.24% | $424.20K | 59,455 |
| Insulet CorpPODD | 0.79% | $410.90K | 2,835 |
| Ascendis Pharma A/S | 0.76% | $393.31K | 1,755 |
| First American Treasury ObligaCash or money market | 0.72% | $373.50K | 373,497 |
| Insmed IncINSM | 0.71% | $368.73K | 3,449 |
| Stoke Therapeutics IncSTOK | 0.60% | $310.61K | 10,049 |
| Viking Therapeutics IncVKTX | 0.54% | $279.53K | 8,538 |
| MBX Biosciences IncMBX | 0.53% | $275.71K | 8,761 |
| Intellia Therapeutics IncNTLA | 0.38% | $195.46K | 13,892 |
| Structure Therapeutics IncGPCR | 0.35% | $180.30K | 4,583 |
| Zealand Pharma A/S | 0.52% | $41.88K | 5,293 |
| Gubra A/S | 0.48% | $39.06K | 4,487 |
| Chugai Pharmaceutical Co Ltd | 1.33% | $4.33K | 13,915 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.